Patients with CRCs that are MMR deficient (dMMR) are found to have higher tumor mutational burden (TMB) and respond to immunotherapy better than patients MMR-proficient (pMMR) CRC (87). This evidence concerns the gene MRC1 and colorectal carcinoma.